Biotech Values

[genisi]

First, it's a highly ranked journal, so good impact. Also, note the JCO authors analysis is on an ITT basis and OS difference is higher than of the ASCO abs.:
ASCO - Median TTP: 28 vs. 11 wks (p=0.012) and OS: 18 vs. 11 mos (p=0.0136).
JCO - Median TTP: 27.5 vs. 10.1 wks (P< .001) and OS: 17.7 vs. 7.6 mos (p= .0052)
Patients who failed 5FU have usually poor RR to later treatment line, there were 25 of them in this trial and the stat-sig increase in OS and TTP in this subgroup is important, imo.

I guess there's the question if the perifosine arm got mostly 2nd-line patients whereas the control arm got mostly 3rd-line patients

The two arms were quite balanced, see in the ASCO abs.